|
May 19
|
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|
|
May 19
|
The Top Corporate Board Directors
|
|
May 16
|
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
|
|
May 15
|
FDA approves Merck’s belzutifan for pheochromocytoma or paraganglioma
|
|
May 15
|
Jefferies not seeing significant impact to Merck, Bristol from draft guidance
|
|
May 15
|
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers
|
|
May 14
|
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)
|
|
May 14
|
Merck (NYSE:MRK) Showcases Broad Cancer Research Portfolio At ASCO Annual Meeting
|
|
May 13
|
Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
|
|
May 12
|
Trump's drug price order is part request, part threat: Analyst
|
|
May 1
|
Top Dividend Stocks To Consider In May 2025
|
|
Apr 29
|
Pfizer offers 'longer-term' opportunity amid tariff uncertainty
|
|
Apr 29
|
Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware
|
|
Apr 29
|
Merck to Spend $1 Billion on New Factory to Make U.S. Supplies of Blockbuster Drug
|
|
Apr 28
|
Merck (NYSE:MRK) Presents Promising KEYTRUDA Trial Data at AACR 2025 Meeting
|
|
Apr 28
|
Temu, Tesla prices, Merck KGaA deal: Trending Tickers
|
|
Apr 27
|
KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
|
|
Apr 27
|
Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks
|
|
Apr 26
|
Akeso survival data for ivonescimab misses expectations, STAT says
|
|
Apr 10
|
Merck (NYSE:MRK) Faces Multiple Shareholder Proposals Ahead Of Annual Meeting
|